SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging
vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-…

VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike
glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern evades antibody-mediated immunity that comes from vaccination or infection with …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …

Efficient therapeutic options are needed to control the spread of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 …

SARS-CoV-2 can mutate to evade immunity, with consequences for the efficacy of emerging
vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved variants with
substitutions in the spike receptor-binding domain (RBD) that affect its affinity for angiotensin-…

Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the
neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is …

Respiratory syncytial virus (RSV) is a top cause of severe lower respiratory tract disease and
mortality in infants and the elderly. Currently, no vaccine or effective treatment exists for RSV…